A phase II trial to evaluate the efficacy and safety of CTP-354 in patients with spasticity associated with multiple sclerosis
Latest Information Update: 29 Oct 2014
At a glance
- Drugs CTP 354 (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- 13 Oct 2014 This trial is expected to be initiated by the end of 2014, according to a Concert Pharmaceuticals media release.
- 06 Aug 2014 New trial record